Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus

Molecular Therapy

Volumn 20, Issue 6, 2012, Pages 1139-1147

  Iankov, Ianko D ^a   Allen, Cory ^a   Federspiel, Mark J ^a   Myers, Rae M ^a   Peng, Kah Whye ^a   Ingle, James N ^a   Russell, Stephen J ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN LAMBDA CHAIN; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; NEUTROPHIL ACTIVATING PROTEIN; ONCOLYTIC VIRUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MEASLES VIRUS; METASTASIS; MOUSE; NONHUMAN; PLEURA EFFUSION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TH1 CELL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALIA; BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI; MEASLES VIRUS;

EID: 84861874828     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.4     Document Type: Article

References (50)

1. Jemal, A, Siegel, R, Xu, J and Ward, E (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Light, RW (2002). Clinical practice. Pleural effusion. N Engl J Med 346: 1971-1977.
3. Neragi-Miandoab, S (2006). Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54: 1-9.
4. Heffner, JE (2008). Diagnosis and management of malignant pleural effusions. Respirology 13: 5-20.
5. Heffner, JE and Klein, JS (2008). Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 83: 235-250. (Pubitemid 351303104)
6. Musani, AI (2009). Treatment options for malignant pleural effusion. Curr Opin Pulm Med 15: 380-387.
7. Galanis, E (2010). Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 88: 620-625.
8. Griffin, D. Measles virus. In: Knipe, DM, Howley, PM, eds. Fields Virology, 4th edn. Philadelphia PA: Lippincott, Williams & Wilkins; 2001. pp 1401-1441.
9. Iankov, ID, Msaouel, P, Allen, C, Federspiel, MJ, Bulur, PA, Dietz, AB et al. (2010). Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat 122: 745-754.
10. Boisgerault, N, Tangy, F and Gregoire, M (2010). New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy 2: 185-199.
11. Grote, D, Cattaneo, R and Fielding, AK (2003). Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colonystimulating factor expression. Cancer Res 63: 6463-6468. (Pubitemid 37255198)
12. Tonello, F, Dundon, WG, Satin, B, Molinari, M, Tognon, G, Grandi, G et al. (1999). The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure. Mol Microbiol 34: 238-246. (Pubitemid 29486242)
13. Satin, B, Del Giudice, G, Della Bianca, V, Dusi, S, Laudanna, C, Tonello, F et al. (2000). The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 191: 1467-1476. (Pubitemid 30257344)
14. Montemurro, P, Barbuti, G, Dundon, WG, Del Giudice, G, Rappuoli, R, Colucci, M et al. (2001). Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells. J Infect Dis 183: 1055-1062. (Pubitemid 32230953)
15. Amedei, A, Cappon, A, Codolo, G, Cabrelle, A, Polenghi, A, Benagiano, M et al. (2006). The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 116: 1092-1101.
16. D'Elios, MM, Amedei, A, Cappon, A, Del Prete, G and de Bernard, M (2007). The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol Med Microbiol 50: 157-164. (Pubitemid 46918654)
17. Iankov, ID, Haralambieva, IH and Galanis, E (2011). Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine 29: 1710-1720.
18. Iankov, ID, Hillestad, ML, Dietz, AB, Russell, SJ and Galanis, E (2009). Converting tumorspecific markers into reporters of oncolytic virus infection. Mol Ther 17: 1395-1403.
19. Mrkic, B, Pavlovic, J, Rülicke, T, Volpe, P, Buchholz, CJ, Hourcade, D et al. (1998). Measles virus spread and pathogenesis in genetically modified mice. J Virol 72: 7420-7427. (Pubitemid 28377873)
20. Myers, RM, Greiner, SM, Harvey, ME, Griesmann, G, Kuffel, MJ, Buhrow, SA et al. (2007). Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 82: 700-710. (Pubitemid 350114828)
21. Msaouel, P, Dispenzieri, A and Galanis, E (2009). Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 11: 43-53.
22. Biology, Table 1-2. Hematology. In: Laboratory Mouse Handbook, by the American Association for Laboratory Animal Science, 2006, p. 2.
23. Grote, D, Russell, SJ, Cornu, TI, Cattaneo, R, Vile, R, Poland, GA et al. (2001). Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97: 3746-3754.
24. Peng, KW, Ahmann, GJ, Pham, L, Greipp, PR, Cattaneo, R and Russell, SJ (2001). Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98: 2002-2007.
25. Peng, KW, TenEyck, CJ, Galanis, E, Kalli, KR, Hartmann, LC and Russell, SJ (2002). Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62: 4656-4662.
26. Phuong, LK, Allen, C, Peng, KW, Giannini, C, Greiner, S, TenEyck, CJ et al. (2003). Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63: 2462-2469. (Pubitemid 36605184)
27. McDonald, CJ, Erlichman, C, Ingle, JN, Rosales, GA, Allen, C, Greiner, SM et al. (2006). A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 99: 177-184. (Pubitemid 44268265)
28. Msaouel, P, Iankov, ID, Allen, C, Morris, JC, von Messling, V, Cattaneo, R et al. (2009). Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69: 82-91.
29. Galanis, E, Hartmann, LC, Cliby, WA, Long, HJ, Peethambaram, PP, Barrette, BA et al. (2010). Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70: 875-882.
30. de Bernard, M and D'Elios, MM (2010). The immune modulating activity of the Helicobacter pylori HP-NAP: Friend or foe? Toxicon 56: 1186-1192.
31. Codolo, G, Mazzi, P, Amedei, A, Del Prete, G, Berton, G, D'Elios, MM et al. (2008). The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol 10: 2355-2363.
32. Del Prete, G, Chiumiento, L, Amedei, A, Piazza, M, D'Elios, MM, Codolo, G et al. (2008). Immunosuppression of TH2 responses in Trichinella spiralis infection by Helicobacter pylori neutrophil-activating protein. J Allergy Clin Immunol 122: 908-913.e5.
33. Lombardi, G, Zustovich, F, Nicoletto, MO, Donach, M, Artioli, G and Pastorelli, D (2010). Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches. Am J Clin Oncol 33: 420-423.
34. van den Heuvel, MM, Smit, HJ, Barbierato, SB, Havenith, CE, Beelen, RH and Postmus, PE (1998). Talc-induced inflammation in the pleural cavity. Eur Respir J 12: 1419-1423. (Pubitemid 29011440)
35. West, SD, Davies, RJ and Lee, YC (2004). Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Curr Opin Pulm Med 10: 305-310. (Pubitemid 38803125)
36. Chung, CL, Chen, YC and Chang, SC (2003). Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion. Chest 123: 1188-1195.
37. Yanagawa, H, Haku, T, Takeuchi, E, Suzuki, Y, Nokihara, H and Sone, S (2000). Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer. Lung Cancer 27: 67-73. (Pubitemid 30067627)
38. Hobohm, U (2005). Fever therapy revisited. Br J Cancer 92: 421-425.
39. Katano, M and Morisaki, T (1998). The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 18(5D): 3917-3925. (Pubitemid 28561081)
40. Kishi, K, Homma, S, Sakamoto, S, Kawabata, M, Tsuboi, E, Nakata, K et al. (2004). Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions. Eur Respir J 24: 263-266. (Pubitemid 39139794)
41. Ren, S, Terman, DS, Bohach, G, Silvers, A, Hansen, C, Colt, H et al. (2004). Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 126: 1529-1539. (Pubitemid 39525027)
42. Brisslert, M, Enarsson, K, Lundin, S, Karlsson, A, Kusters, JG, Svennerholm, AM et al. (2005). Helicobacter pylori induce neutrophil transendothelial migration: role of the bacterial HP-NAP. FEMS Microbiol Lett 249: 95-103. (Pubitemid 40981885)
43. Polenghi, A, Bossi, F, Fischetti, F, Durigutto, P, Cabrelle, A, Tamassia, N et al. (2007). The neutrophil-activating protein of Helicobacter pylori crosses endothelia to promote neutrophil adhesion in vivo. J Immunol 178: 1312-1320. (Pubitemid 46154601)
44. Basu, A, Mohanty, S and Sun, B (2001). Differential sensitivity of breast cancer cells to tumor necrosis factor-alpha: involvement of protein kinase C. Biochem Biophys Res Commun 280: 883-891. (Pubitemid 32924515)
45. Burow, ME, Tang, Y, Collins-Burow, BM, Krajewski, S, Reed, JC, McLachlan, JA et al. (1999). Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells. Carcinogenesis 20: 2057-2061. (Pubitemid 29535305)
46. Iankov, ID, Blechacz, B, Liu, C, Schmeckpeper, JD, Tarara, JE, Federspiel, MJ et al. (2007). Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 15: 114-122. (Pubitemid 46043656)
47. Zuniga, A, Wang, Z, Liniger, M, Hangartner, L, Caballero, M, Pavlovic, J et al. (2007). Attenuated measles virus as a vaccine vector. Vaccine 25: 2974-2983. (Pubitemid 46482728)
48. Dingli, D, Peng, KW, Harvey, ME, Greipp, PR, O'Connor, MK, Cattaneo, R et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103: 1641-1646. (Pubitemid 38268954)
49. Duprex, WP, McQuaid, S, Hangartner, L, Billeter, MA and Rima, BK (1999). Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 73: 9568-9575. (Pubitemid 29487112)
50. Langfield, KK, Walker, HJ, Gregory, LC and Federspiel, MJ (2011). Manufacture of measles viruses. Methods Mol Biol 737: 345-366.